药 物 回 收
|
| |
| Singapore: Recall of Apo-Acyclovir Tablet 800mg (English only) |
| |
Health Sciences Authority (HSA) announces that Pharmaforte Singapore Pte Ltd is recalling one batch of Apo-Acyclovir Tablet 800mg (batch number: TE5062) to the retail level. Following the recall of one batch of Apo-Acyclovir tablets on 27 Apr 2022, one additional batch of Apo-Acyclovir tablets was found to contain N-nitrosodimethylamine (NDMA) at levels above acceptable level. As a precautionary measure, the affected batch is recalled.
Please refer to the following website in HSA for details:
http://www.hsa.gov.sg/announcements/product-recall/recall-of-apo-acyclovir-tablet-800mg-tablets-(1-august-2022)
In Hong Kong, Apo-Acyclovir Tab 800mg (HK-58228) is a pharmaceutical product registered by Hind Wing Co Ltd (Hind Wing). The product is a prescription-only medicine.
On 29 Jul 2022, the Department of Health (DH) endorsed Hind Wing to recall a total of 3 batches of the following 2 products from the market as a precautionary measure due to the
presence of an impurity (NDMA) in the products:
- Apo-Acyclovir Tab 200mg (HK-43427) (batch number: TF4466)
- Apo-Acyclovir Tab 800mg (HK-58228) (batch number: TE5062, TH6119)
A recall statement was issued on the same date.
Previously on 28 Apr 2022, the DH endorsed Hind Wing to recall a total of 4 batches of the following 2 products from the market as a precautionary measure due to the presence of an impurity (NDMA) in the products:
- Apo-Acyclovir Tab 200mg (HK-43427) (batch number: RH9368, RH9370)
- Apo-Acyclovir Tab 800mg (HK-58228) (batch number: RP8516, RP8517)
A press statement was issued on the same date.
Related news was previously issued by Health Canada and HSA, and was posted on the Drug Office website on 29 Apr 2022 and 29 Jul 2022.
Ends/Tuesday, Aug 2, 2022
Issued at HKT 14:00
|
| |
|
